Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer

Isuru S. Jayaratna, Neema Navai, Colin P.N. Dinney

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Muscle invasive bladder cancer (MIBC) is an aggressive disease that frequently requires radical cystectomy (RC) to achieve durable cure rates. Surgery is most effective when performed in organ-confined disease, with the best outcomes for those patients with a pT0 result. The goals of neoadjuvant chemotherapy (NC) are to optimize surgical outcomes for a malignancy with limited adjuvant therapies and a lack of effective salvage treatments. Despite level 1 evidence demonstrating a survival benefit, the utilization of NC has been hampered by several issues, including, the inability to predict responders and the perception that NC may delay curative surgery. In this article, we review the current efforts to identify patients that are most likely to derive a benefit from NC, in order to create a risk-adapted paradigm that reserves NC for those who need it.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalTranslational Andrology and Urology
Issue number3
StatePublished - 2015
Externally publishedYes


  • Bladder cancer
  • Chemotherapy
  • Neoadjuvant therapy
  • Risk assessment


Dive into the research topics of 'Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this